Abcam (ABCM), which announced on June 23 that its board had unanimously decided to initiate a process to explore strategic alternatives for the company after “having listened to and extensively engaged with shareholders,” is attracting initial interest from Danaher (DHR) and Agilent (A) and has separately approached companies including Germany’s Merck KGaA (MKGAY) to gauge their interest, according to Bloomberg’s Dinesh Nair, Michelle Davis and Eyk Henning, citing sources.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ABCM:
- Abcam confirms Dr. Jonathan Milner withdrew EGM requisition, resolutions
- Starboard supports Abcam running full sale process
- Abcam backs FY 23 revenue view, sees FY24 revenue up 11.3%-13.4% vs. 2019
- Abcam to explore strategic alternatives, including sale of company
- Jonathan Milner urges Abcam shareholders to vore for his proposals
